The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis

Background: Despite meticulous surgery for non-small cell lung cancer (NSCLC), relapse is as high as 70% at 5 years. Many institutions do not conduct reflexive molecular testing on early stage specimens, although targeted gene therapy may extend life by years in the event of recurrence. This ultimat...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Anna L. McGuire, Melissa K. McConechy, Barb L. Melosky, John C. English, James J. Choi, Defen Peng, John Yee, Benjamin L. S. Furman, Rosalia Aguirre Hernandez, Pedro Feijao, David Mulder, Curtis Hughesman, Stephen Yip
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2022-04-01
Serie:	Current Oncology
Soggetti:	lung cancer next-generation sequencing biomarker targeted therapy
Accesso online:	https://www.mdpi.com/1718-7729/29/4/215
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!